Aurora Cannabis Past Earnings Performance
Past criteria checks 3/6
Aurora Cannabis has been growing earnings at an average annual rate of 13.4%, while the Pharmaceuticals industry saw earnings growing at 10.5% annually. Revenues have been growing at an average rate of 1.9% per year. Aurora Cannabis's return on equity is 71.5%, and it has net margins of 148.9%.
Key information
13.4%
Earnings growth rate
26.4%
EPS growth rate
| Pharmaceuticals Industry Growth | 7.3% |
| Revenue growth rate | 1.9% |
| Return on equity | 71.5% |
| Net Margin | 148.9% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Aurora Cannabis makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 276 | 411 | 126 | 5 |
| 30 Sep 23 | 273 | 374 | 125 | 6 |
| 30 Jun 23 | 258 | 331 | 127 | 6 |
| 31 Mar 23 | 233 | -265 | 135 | 7 |
| 31 Dec 22 | 212 | -1,748 | 163 | 8 |
| 30 Sep 22 | 210 | -1,757 | 180 | 8 |
| 30 Jun 22 | 221 | -1,718 | 176 | 10 |
| 31 Mar 22 | 226 | -1,233 | 185 | 11 |
| 31 Dec 21 | 231 | -381 | 189 | 12 |
| 30 Sep 21 | 238 | -607 | 188 | 13 |
| 30 Jun 21 | 245 | -692 | 195 | 11 |
| 31 Mar 21 | 257 | -2,387 | 206 | 16 |
| 31 Dec 20 | 275 | -2,359 | 241 | 18 |
| 30 Sep 20 | 263 | -3,342 | 300 | 23 |
| 30 Jun 20 | 269 | -3,231 | 346 | 26 |
| 31 Mar 20 | 299 | -1,405 | 372 | 24 |
| 31 Dec 19 | 291 | -1,430 | 397 | 22 |
| 30 Sep 19 | 290 | -385 | 376 | 17 |
| 30 Jun 19 | 246 | -294 | 365 | 15 |
| 31 Mar 19 | 168 | -211 | 327 | 10 |
| 31 Dec 18 | 119 | -72 | 253 | 7 |
| 30 Sep 18 | 77 | 174 | 187 | 5 |
| 30 Jun 18 | 55 | 72 | 110 | 2 |
| 31 Mar 18 | 42 | -13 | 69 | 1 |
| 31 Dec 17 | 31 | 7 | 45 | 0 |
| 30 Sep 17 | 23 | -4 | 31 | 0 |
| 30 Jun 17 | 18 | -13 | 25 | 0 |
| 31 Mar 17 | 13 | -16 | 19 | 0 |
| 31 Dec 16 | 8 | -13 | 13 | 0 |
| 30 Sep 16 | 5 | -10 | 8 | 1 |
| 30 Jun 16 | 1 | -6 | 6 | 1 |
| 31 Mar 16 | 0 | 0 | 5 | 1 |
| 31 Dec 15 | 0 | -3 | 4 | 1 |
| 30 Sep 15 | 0 | -10 | 4 | 1 |
| 30 Jun 15 | 0 | -10 | 4 | 0 |
Quality Earnings: 21P has a high level of non-cash earnings.
Growing Profit Margin: 21P became profitable in the past.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 21P has become profitable over the past 5 years, growing earnings by 13.4% per year.
Accelerating Growth: 21P has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: 21P has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (2.6%).
Return on Equity
High ROE: 21P's Return on Equity (71.5%) is considered outstanding.